Sage Therapeutics Quarterly Income Statements Chart
Quarterly
|
Annual
Sage Therapeutics Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| product revenue | 442,000 | 843,000 | 600,000 | 1,690,000 | 1,985,000 | 2,716,000 | 2,460,000 | 3,294,000 | 2,865,000 | 1,739,000 | 1,501,000 | 1,582,000 | 1,642,000 | 1,440,000 | 1,643,000 | 1,583,000 | 1,686,000 | 1,639,000 | 1,089,000 | 2,286,000 | 1,960,000 | 1,478,000 | 519,000 | |||||||||||||||||||||
| collaboration revenue - related party | 13,827,000 | 11,426,000 | 11,028,000 | 7,420,000 | 6,212,000 | |||||||||||||||||||||||||||||||||||||||
| other revenue | 236,000 | |||||||||||||||||||||||||||||||||||||||||||
| total revenues | 14,063,000 | 12,816,000 | 11,871,000 | 8,654,000 | ||||||||||||||||||||||||||||||||||||||||
| operating costs and expenses: | ||||||||||||||||||||||||||||||||||||||||||||
| cost of revenues | 655,000 | 1,489,000 | 5,278,000 | 1,407,000 | 1,269,000 | |||||||||||||||||||||||||||||||||||||||
| research and development | 22,759,000 | 37,022,000 | 54,576,000 | 62,564,000 | 71,734,000 | 64,330,000 | 101,919,000 | 97,161,000 | 92,826,000 | 89,295,000 | 81,553,000 | 77,297,000 | 78,018,000 | 75,443,000 | 83,497,000 | 66,170,000 | 58,056,000 | 81,706,000 | 74,078,000 | 73,320,000 | 63,610,000 | 91,250,000 | 102,108,000 | 89,059,000 | 86,398,000 | 88,805,000 | 75,052,000 | 68,980,000 | 49,270,000 | 50,891,000 | 58,286,000 | 55,900,000 | 45,200,000 | 42,004,000 | 29,075,000 | 26,096,000 | 23,581,000 | 20,376,000 | 17,478,000 | 18,603,000 | 12,900,000 | 8,945,000 | 6,601,000 | 4,381,000 |
| selling, general and administrative | 57,591,000 | 54,645,000 | 53,219,000 | 55,983,000 | 52,574,000 | 55,109,000 | 78,142,000 | 75,565,000 | 65,708,000 | 67,329,000 | 61,482,000 | 52,411,000 | 46,477,000 | 51,599,000 | 48,706,000 | 43,346,000 | 39,847,000 | 53,498,000 | 35,099,000 | 38,224,000 | 70,130,000 | 85,129,000 | 88,502,000 | 88,227,000 | ||||||||||||||||||||
| restructuring | 513,000 | -213,000 | 33,599,000 | -130,000 | -529,000 | 28,402,000 | ||||||||||||||||||||||||||||||||||||||
| total operating costs and expenses | 81,518,000 | 115,010,000 | 113,073,000 | 119,954,000 | 125,577,000 | 120,046,000 | 214,565,000 | 172,931,000 | 158,764,000 | 156,767,000 | 143,219,000 | 129,908,000 | 124,781,000 | 127,129,000 | 132,334,000 | 109,664,000 | 98,090,000 | 135,210,000 | 108,797,000 | 140,056,000 | 133,910,000 | 176,598,000 | 190,747,000 | 177,330,000 | ||||||||||||||||||||
| income from operations | -67,455,000 | -102,194,000 | -101,202,000 | -111,300,000 | -117,675,000 | -42,074,000 | -211,849,000 | -170,457,000 | -155,470,000 | -153,902,000 | -141,480,000 | -128,407,000 | -123,199,000 | -125,487,000 | -130,894,000 | -108,021,000 | -96,507,000 | 973,976,000 | -107,158,000 | -138,967,000 | -131,624,000 | -174,638,000 | -187,177,000 | -176,457,000 | -169,852,000 | -164,227,000 | -128,745,000 | -22,147,000 | -78,119,000 | -70,449,000 | -74,373,000 | -70,854,000 | -57,480,000 | -56,378,000 | -38,064,000 | -35,006,000 | -30,714,000 | -28,612,000 | -24,082,000 | -25,059,000 | -16,897,000 | -12,361,000 | -9,470,000 | -6,188,000 |
| yoy | -42.68% | 142.89% | -52.23% | -34.70% | -24.31% | -72.66% | 49.74% | 32.75% | 26.19% | 22.64% | 8.09% | 18.87% | 27.66% | -112.88% | 22.15% | -22.27% | -26.68% | -657.71% | -42.75% | -21.25% | -22.51% | 6.34% | 45.39% | 696.75% | 117.43% | 133.11% | 73.11% | -68.74% | 35.91% | 24.96% | 95.39% | 102.41% | 87.15% | 97.04% | 58.06% | 39.69% | 81.77% | 131.47% | 154.30% | 304.96% | ||||
| qoq | -33.99% | 0.98% | -9.07% | -5.42% | 179.69% | -80.14% | 24.28% | 9.64% | 1.02% | 8.78% | 10.18% | 4.23% | -1.82% | -4.13% | 21.17% | 11.93% | -109.91% | -1008.92% | -22.89% | 5.58% | -24.63% | -6.70% | 6.08% | 3.89% | 3.43% | 27.56% | 481.32% | -71.65% | 10.89% | -5.28% | 4.97% | 23.27% | 1.95% | 48.11% | 8.74% | 13.97% | 7.35% | 18.81% | -3.90% | 48.30% | 36.70% | 30.53% | 53.04% | |
| operating margin % | -1489.18% | -53.96% | -7800.04% | -6889.94% | 87.81% | -6538.01% | -12760.97% | -5757.83% | -8910.10% | -5243.05% | -20212.71% | |||||||||||||||||||||||||||||||||
| interest income | 5,223,000 | 6,398,000 | 7,642,000 | 8,431,000 | 9,204,000 | 9,467,000 | 10,274,000 | 10,173,000 | 8,830,000 | 6,793,000 | 4,127,000 | 2,102,000 | 1,168,000 | 751,000 | 692,000 | 732,000 | 708,000 | 834,000 | 1,347,000 | 2,686,000 | 4,729,000 | 5,915,000 | 7,227,000 | 8,220,000 | 6,442,000 | 5,851,000 | 5,817,000 | 5,137,000 | 3,529,000 | 1,043,000 | 677,000 | 672,000 | 707,000 | 494,000 | 275,000 | 266,000 | 175,000 | 63,000 | 53,000 | 41,000 | 21,000 | 4,000 | 3,000 | 1,000 |
| other income | 18,000 | 18,000 | 9,000 | 15,000 | -12,000 | -99,000 | -55,000 | -41,000 | -188,000 | -37,000 | 30,000 | 45,000 | -24,000 | 24,000 | 31,000 | 44,000 | 35,000 | 85,000 | 76,000 | -66,000 | 155,000 | 70,000 | -8,000 | 16,000 | 4,000 | -12,000 | 10,000 | 32,000 | -8,000 | -16,000 | -23,000 | -20,000 | -5,000 | -17,000 | -7,000 | -7,000 | -4,000 | -13,000 | -6,000 | -9,000 | 5,000 | -4,000 | -1,000 | -5,000 |
| net income | -62,214,000 | -95,778,000 | -93,551,000 | -102,854,000 | -108,483,000 | -32,706,000 | -201,630,000 | -160,325,000 | -146,828,000 | -147,146,000 | -137,323,000 | -126,260,000 | -122,055,000 | -124,712,000 | -130,171,000 | -107,245,000 | -95,764,000 | 974,895,000 | -105,735,000 | -136,347,000 | -126,740,000 | -168,653,000 | -179,958,000 | -168,221,000 | -163,406,000 | -158,388,000 | -122,918,000 | -16,978,000 | -74,598,000 | -69,422,000 | -73,719,000 | -70,202,000 | -56,778,000 | -55,901,000 | -37,796,000 | -34,747,000 | ||||||||
| yoy | -42.65% | 192.85% | -53.60% | -35.85% | -26.12% | -77.77% | 46.83% | 26.98% | 20.30% | 17.99% | 5.49% | 17.73% | 27.45% | -112.79% | 23.11% | -21.34% | -24.44% | -678.05% | -41.24% | -18.95% | -22.44% | 6.48% | 46.40% | 890.82% | 119.05% | 128.15% | 66.74% | -75.82% | 31.39% | 24.19% | 95.04% | 102.04% | ||||||||||||
| qoq | -35.04% | 2.38% | -9.04% | -5.19% | 231.69% | -83.78% | 25.76% | 9.19% | -0.22% | 7.15% | 8.76% | 3.45% | -2.13% | -4.19% | 21.38% | 11.99% | -109.82% | -1022.02% | -22.45% | 7.58% | -24.85% | -6.28% | 6.98% | 2.95% | 3.17% | 28.86% | 623.98% | -77.24% | 7.46% | -5.83% | 5.01% | 23.64% | 1.57% | 47.90% | 8.77% | |||||||||
| net income margin % | -1372.85% | -41.95% | -7423.78% | -6480.40% | 87.89% | -6451.19% | -12520.39% | -5544.18% | -8604.74% | -5040.84% | -19269.30% | |||||||||||||||||||||||||||||||||
| net income per share | -1.01 | -1.56 | -1.53 | -1.7 | -1.8 | -0.54 | -3.37 | -2.68 | -2.46 | -2.47 | -2.31 | -2.13 | -2.07 | -2.11 | -2.21 | -1.83 | -1.64 | 18.76 | -2.03 | -2.63 | -2.44 | -3.25 | -3.48 | -3.28 | -3.37 | -3.4 | -2.63 | -0.36 | -1.68 | -1.72 | -1.97 | -1.88 | -1.52 | -1.55 | -1.15 | -1.08 | -0.97 | -1 | -0.84 | -0.9 | -0.66 | 1.41 | -0.5 | -4.57 |
| weighted-average number of common shares outstanding—basic and diluted | 61,857,573 | 60,765,913 | 61,116,524 | 60,538,319 | 60,136,198 | 59,836,441 | 59,912,378 | 59,769,640 | 59,674,127 | 59,428,123 | 59,266,322 | 59,028,858 | 58,819,548 | 58,582,569 | 58,374,219 | 51,981,468 | 51,926,074 | 51,908,760 | 50,833,837 | 51,704,687 | 51,257,640 | 48,491,834 | 46,121,194 | 46,706,770 | 46,541,716 | 44,325,371 | 38,113,678 | |||||||||||||||||
| comprehensive loss: | ||||||||||||||||||||||||||||||||||||||||||||
| other comprehensive items: | ||||||||||||||||||||||||||||||||||||||||||||
| unrealized gain on marketable securities | -102 | -657 | 1,592 | 96 | 27 | 2,921 | 1,909 | -556 | 5,118 | -49 | -651 | -531 | -763 | 2,501 | -2,087 | -482 | 202 | 1,681 | 409 | -258 | -112 | 40 | -156 | -14 | 52 | 14 | 21 | 39 | ||||||||||||||||
| total comprehensive loss | -62,316 | -96,435 | -91,959 | -102,758 | -108,456 | -29,785 | -199,721 | -160,881 | -141,710 | -99,465.25 | -138,334 | -128,931 | -130,596 | -83,475.25 | -130,192 | -107,294 | -96,415 | -92,292.75 | -106,498 | -133,846 | -128,827 | -169,135 | -179,756 | -166,540 | -162,997 | -158,646 | -123,030 | -16,938 | -74,754 | -69,436 | -73,667 | -70,188 | -56,757 | -55,968 | -37,870 | -34,708 | ||||||||
| consists of related-party amounts of 0.2m for the quarter ended march 31, 2025 (see note 7). | ||||||||||||||||||||||||||||||||||||||||||||
| other collaboration revenue | 948,000 | 634,000 | ||||||||||||||||||||||||||||||||||||||||||
| total revenue | 7,902,000 | 77,972,000 | 2,716,000 | 2,474,000 | 1,109,186,000 | 1,639,000 | 1,089,000 | 2,286,000 | 1,960,000 | 3,570,000 | 873,000 | |||||||||||||||||||||||||||||||||
| yoy | 56491.12% | -54.09% | 24.74% | |||||||||||||||||||||||||||||||||||||||||
| qoq | -89.87% | 2770.84% | 9.78% | 67574.56% | 50.51% | -52.36% | 16.63% | -45.10% | 308.93% | |||||||||||||||||||||||||||||||||||
| collaboration revenue | 3,500 | 14,000 | 2,092,000 | 354,000 | 465,000 | 273,000 | 90,000,000 | |||||||||||||||||||||||||||||||||||||
| cost of goods sold | 334,750 | 905,000 | 205,000 | 230,000 | 143,000 | 184,000 | 200,000 | 286,000 | 87,000 | 131,000 | 148,000 | 187,000 | 136,000 | 149,000 | 110,000 | 170,000 | 219,000 | 137,000 | 44,000 | |||||||||||||||||||||||||
| total other comprehensive gain | 1,617.75 | 1,909 | -556 | 5,118 | -49 | -651 | -531 | -763 | 2,501 | -2,087 | -482 | 202 | 1,681 | 409 | -258 | -112 | 40 | -156 | -14 | 52 | 14 | 21 | 39 | |||||||||||||||||||||
| unrealized loss on marketable securities | 4,677 | -1,011 | -2,671 | -8,541 | -180.25 | -21 | -67 | -74 | ||||||||||||||||||||||||||||||||||||
| total other comprehensive loss | 4,677 | -1,011 | -2,671 | -8,541 | -180.25 | -21 | -67 | -74 | ||||||||||||||||||||||||||||||||||||
| operating expenses: | ||||||||||||||||||||||||||||||||||||||||||||
| general and administrative | 83,919,000 | 75,695,000 | 53,693,000 | 43,167,000 | 28,849,000 | 19,558,000 | 16,087,000 | 14,954,000 | 12,280,000 | 14,374,000 | 8,989,000 | 8,910,000 | 7,133,000 | 8,236,000 | 6,604,000 | 6,456,000 | 3,997,000 | 3,416,000 | 2,869,000 | 1,807,000 | ||||||||||||||||||||||||
| total operating expenses | 170,317,000 | 164,500,000 | 128,745,000 | 112,147,000 | 78,119,000 | 70,449,000 | 74,373,000 | 70,854,000 | 57,480,000 | 56,378,000 | 38,064,000 | 35,006,000 | 30,714,000 | 28,612,000 | 24,082,000 | 25,059,000 | 16,897,000 | 12,361,000 | 9,470,000 | 6,188,000 | ||||||||||||||||||||||||
| weighted-average common shares outstanding—basic and diluted | 37,470,912 | 37,361,129 | 37,269,148 | 32,975,897 | ||||||||||||||||||||||||||||||||||||||||
| weighted-average shares outstanding—basic and diluted | 32,062,298 | |||||||||||||||||||||||||||||||||||||||||||
| net income and comprehensive loss | -30,543,000 | -28,562,000 | -24,035,000 | -25,027,000 | -16,871,000 | -12,361,000 | -9,468,000 | -6,192,000 | ||||||||||||||||||||||||||||||||||||
| weighted-average number of common shares used in net income per share—basic and diluted | 31,643,216 | |||||||||||||||||||||||||||||||||||||||||||
| accretion of redeemable convertible preferred stock to redemption value | -391,000 | -1,577,000 | ||||||||||||||||||||||||||||||||||||||||||
| net income attributable to common stockholders | -28,562,000 | -24,035,000 | -25,027,000 | -16,871,000 | -12,361,000 | -9,859,000 | -7,769,000 | |||||||||||||||||||||||||||||||||||||
| weighted-average number of common shares used in net income per share attributable to common stockholders—basic and diluted | 33,492,795 | 27,778,288 | 28,737,743 | 27,860,332 | 25,655,883 | 21,574,347 | 19,581,624 | 1,700,517 | ||||||||||||||||||||||||||||||||||||
We provide you with 20 years income statements for Sage Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Sage Therapeutics stock. Explore the full financial landscape of Sage Therapeutics stock with our expertly curated income statements.
The information provided in this report about Sage Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.